Abstract: Hepatitis B virus ( HBV) infection is a global public health issue, especially in the Asian-Pacific region. At present, entecavir, tenofovir, and pegylated interferon are the first-line antiviral drugs recommended by related guidelines for the prevention and treatment of hepatitis B; however, different national/regional policies, economic level, coverage of health insurance, and medical level have caused the difference in antiviral regimens. Therefore, we have established a long-term follow-up cohort of hepatitis B to evaluate the efficacy of different treatment regimens, in order to improve the cure rate of hepatitis B and reduce the incidence rates of liver cirrhosis, liver cancer, and end-stage liver disease. Real-world data from cohort study help to understand the differences between guidelines and clinical practice, provide a reference for HBV guidelines, and balance clinical effect and cost-effectiveness.